Introduction
Non-vitamin K antagonist oral anticoagulants (NOAC) are increasingly used in atrial fibrillation (AF), regardless of age, and now they are preferred over vitamin K antagonists (VKA) [1] . AF occurs in 10-17% of the population over 80 years old [1, 2] and increases the risk of ischemic stroke at least 4-fold [3] .
While treating very elderly patients with NOAC, it is important to consider several concomitant diseases such as increased risk of falls, dementia, chronic kidney disease (CKD), liver disease. as well as drug-drug interactions, which affects the safety of anticoagulation [4] .
A large global registry showed that 82.3% of patients over 85 with newly diagnosed AF receive anticoagulation, of which nearly 46% are treated with NOAC [5] , most commonly with apixaban [6] . The current European Society of Cardiology guidelines indicate that very elderly patients with AF do better on oral anticoagulants than not and on NOAC rather than VKA [7] . In the elderly with AF safety concerns represent the main reason for insufficient use of oral anticoagulants [8] .
The purpose of this case series was to evaluate the efficacy and safety of apixaban, rivaroxaban and dabigatran in real-life AF patients aged 85 or more, who were followed in a single institution on a long-term basis.
Methods
We enrolled 40 consecutive patients over 85 years old, who were diagnosed with nonvalvular AF and in whom NOAC treatment was initiated since January 2015. We excluded patients with a history of serious gastrointestinal or intracranial bleeding, known cancer, hemoglobin <9 g/dl, thrombocytopenia <50 x10 3 /μl, CKD stage 5, or potent drug-drug interactions. All patients were recruited in outpatient clinics at the John Paul II Hospital in Krakow, Poland.
The study protocol was approved by the bioethical committee and all patients gave informed consent to participate in the study.
The HAS-BLED and CHA2DS2-VASc scores were used to evaluate bleeding and thromboembolism risk, respectively. Definitions of all comorbidties were derived from our previous work [9] . Major bleeding and clinically relevant non-major bleedings (CRNMB) were defined according to the International Society on Thrombosis and Hemostasis criteria [10] .
The follow-up period was carried out on the six-month basis (a visit at the center or a telephone contact). We recorded ischemic stroke, transient ischemic attack ( Continuous variables are expressed as median (IQR, interquartile range), or mean (standard deviation) whereas the qualitative variables are shown as numbers (percentages). The two patient groups were compared using Mann-Whitney U-test or chi-square test or Fisher's exact test. A P value of l<0.05 was considered significant.
Results and discussion
We enrolled 40 patients aged from 85 to 93 years, and women represented 57.5% (Table 1) .
Three-fourths of the study group had permanent AF and all patients had a high thromboembolic risk. Patients received most frequently apixaban (2.5 mg bid, 50% or 5 mg bid, 12.5%), while dabigatran (110 mg bid, 20%) or rivaroxaban (15 mg/d, 17.5%) were used less commonly. Fourteen patients (35.0%) used the inappropriate NOAC dosing regimen, with the predominance (78.5%) of those on apixaban 2.5 mg bid instead of apixaban 5 mg bid. There were no differences in demographic, clinical and laboratory variables between patients on apixaban versus those receiving dabigatran or rivaroxaban (Table 1) This case-series shows acceptable rates of ischemic cerebrovascular events as well as major bleeding and/or CRNMB in AF patients aged 85 or older, who were treated with NOACs.
The rates of major bleedings were similar to those reported in seminal NOAC trials for AF patients over 75 (5.7%/year [11] ), however stroke or TE occurred more common in our study (1.7%/year [11] ). We failed to demonstrate better safety of apixaban compared with rivaroxaban 15 mg qd and dabigatran 110 mg bid in very elderly AF patients.
Kim et al. reported 403 AF patients treated with NOACs at the mean age of 83.4±3.2 years, who received dabigatran (35%), rivaroxaban (39%) or apixaban (26%) [13] and they found a similar thromboembolic risk (2.4%/year) compared to the present study with lower risk of major bleeds and GI bleeds (2%/year each). Since our patients were older, all above 85 years, it might be speculated that this difference contributes to higher bleeding risk in the current series, together with low level of knowledge on AF and anticoagulation related in part with cognitive impairment [8] .
Regarding dosing regimens, the current guidelines recommend using reduced-dose NOACs in elderly patients mainly with impaired renal function [1, 5] . However, reduced-dose dabigatran should be used above 80 years of age, while apixaban 2.5 mg bid is recommended in the presence of creatinine ≥ 133 μmol/l or weight ≤ 60 kg in such elderly AF patients [1] .
Overrepresentation of AF patients on reduced, off-label doses of NOACs is observed worldwide, which leads to increased stroke risk with unaltered bleeding risk [5, 12] . In the present study, we did not observe an increase in embolic events, however we noticed an increased risk of bleeding in patients who received incorrect reduced dose of apixaban.
Our novel finding is that elevated GDF-15 at baseline in very elderly AF patients while starting NOAC might be useful in the prediction of bleeding, which is consistent with Hijazi et al. [13] who however analyzed patients aged on average 72 years. GDF-15, known to be a marker of oxidative stress and inflammation, has been shown to be independently associated with bleeding and thromboembolic events in AF. The current finding, when validated in a larger group, might help identify patients aged 85 years or more in whom closer surveillance is needed.
The study has several limitations. First, the group was small but the findings are representative for Polish very elderly AF patients. Secondly, our findings could not be referred to elderly AF patients with prior major bleeds, who were ineligible. Given large differences between regions in Poland in the anticoagulation used in AF in part related with the type of center [14] , the rates in other centers might be higher. We did not measure NOAC concentrations, which might help optimize anticoagulation in a high-risk groups [15] .
In conclusion, our single center experience supports use of NOAC as a safe and effective anticoagulation treatment in AF patients aged 85 or older. 
